Do analysts recommend MBAI or NTRB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is MBAI or NTRB more profitable?

Check-Cap has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Check-Cap's return on equity of 0.00% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Nutriband -448.25% -112.64% -97.86%

Do analysts prefer MBAI or NEPH?

Nephros has a consensus price target of $6.00, indicating a potential upside of 76.47%. Given Nephros' stronger consensus rating and higher probable upside, analysts clearly believe Nephros is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nephros 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is MBAI or NEPH more profitable?

Nephros has a net margin of 4.06% compared to Check-Cap's net margin of 0.00%. Nephros' return on equity of 7.66% beat Check-Cap's return on equity. Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Nephros 4.06% 7.66% 5.86%

Do analysts rate TELA or MBAI?

TELA Bio currently has a consensus price target of $2.20, suggesting a potential upside of 204.96%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts plainly believe TELA Bio is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TELA Bio 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TELA or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to TELA Bio's net margin of -49.30%. Check-Cap's return on equity of 0.00% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -49.30% -1,320.81% -55.83% Check-Cap N/A N/A N/A

Do analysts rate NSPR or MBAI?

InspireMD currently has a consensus price target of $4.50, suggesting a potential upside of 543.78%. Given InspireMD's stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InspireMD 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NSPR or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. Check-Cap's return on equity of 0.00% beat InspireMD's return on equity. Company Net Margins Return on Equity Return on Assets InspireMD -413.96% -69.42% -57.68% Check-Cap N/A N/A N/A

Do analysts prefer MBAI or PETV?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is MBAI or PETV more profitable?

Check-Cap has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Check-Cap's return on equity of 0.00% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A PetVivo -902.82% -4,813.07% -281.78%

Does the media prefer MBAI or PETV?

In the previous week, PetVivo had 4 more articles in the media than Check-Cap. MarketBeat recorded 5 mentions for PetVivo and 1 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.36 beat PetVivo's score of 0.32 indicating that Check-Cap is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Check-Cap 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PetVivo 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Check-Cap (MBAI) Competitors

$1.14 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.14 0.00 (0.00%)

As of 07/2/2026 07:05 PM Eastern

Compare

MBAI vs. NTRB, NEPH, TELA, NSPR, and PETV

Should you buy Check-Cap stock or one of its competitors? MarketBeat compares Check-Cap with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Check-Cap include Nutriband (NTRB), Nephros (NEPH), TELA Bio (TELA), InspireMD (NSPR), and PetVivo (PETV). These companies are all part of the "medical equipment" industry.

How does Check-Cap compare to Nutriband?

Check-Cap (NASDAQ:MBAI) and Nutriband (NASDAQ:NTRB) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Check-Cap had 1 more articles in the media than Nutriband. MarketBeat recorded 1 mentions for Check-Cap and 0 mentions for Nutriband. Check-Cap's average media sentiment score of 0.36 beat Nutriband's score of 0.00 indicating that Check-Cap is being referred to more favorably in the media.

Company	Overall Sentiment
Check-Cap	Neutral
Nutriband	Neutral

Check-Cap has higher earnings, but lower revenue than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Nutriband	$1.80M	20.64	-$8.23M	-$2.58	N/A

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 0.5% of Check-Cap shares are held by insiders. Comparatively, 52.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Check-Cap has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Nutriband has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market.

Check-Cap has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Check-Cap's return on equity of 0.00% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Nutriband	-448.25%	-112.64%	-97.86%

Summary

Check-Cap beats Nutriband on 7 of the 13 factors compared between the two stocks.

How does Check-Cap compare to Nephros?

Check-Cap (NASDAQ:MBAI) and Nephros (NASDAQ:NEPH) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Nephros has a consensus price target of $6.00, indicating a potential upside of 76.47%. Given Nephros' stronger consensus rating and higher probable upside, analysts clearly believe Nephros is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Check-Cap has higher earnings, but lower revenue than Nephros. Check-Cap is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Nephros	$19.12M	1.93	$1.19M	$0.07	48.57

Nephros has a net margin of 4.06% compared to Check-Cap's net margin of 0.00%. Nephros' return on equity of 7.66% beat Check-Cap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Nephros	4.06%	7.66%	5.86%

Check-Cap has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Nephros has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 0.5% of Check-Cap shares are held by insiders. Comparatively, 6.7% of Nephros shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Check-Cap had 1 more articles in the media than Nephros. MarketBeat recorded 1 mentions for Check-Cap and 0 mentions for Nephros. Check-Cap's average media sentiment score of 0.36 beat Nephros' score of 0.00 indicating that Check-Cap is being referred to more favorably in the media.

Company	Overall Sentiment
Check-Cap	Neutral
Nephros	Neutral

Summary

Nephros beats Check-Cap on 12 of the 15 factors compared between the two stocks.

How does Check-Cap compare to TELA Bio?

TELA Bio (NASDAQ:TELA) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Check-Cap has a net margin of 0.00% compared to TELA Bio's net margin of -49.30%. Check-Cap's return on equity of 0.00% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-49.30%	-1,320.81%	-55.83%
Check-Cap	N/A	N/A	N/A

TELA Bio currently has a consensus price target of $2.20, suggesting a potential upside of 204.96%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts plainly believe TELA Bio is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Check-Cap had 1 more articles in the media than TELA Bio. MarketBeat recorded 1 mentions for Check-Cap and 0 mentions for TELA Bio. Check-Cap's average media sentiment score of 0.36 beat TELA Bio's score of 0.00 indicating that Check-Cap is being referred to more favorably in the news media.

Company	Overall Sentiment
TELA Bio	Neutral
Check-Cap	Neutral

Check-Cap has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.81M	0.40	-$38.83M	-$0.79	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

TELA Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

94.3% of TELA Bio shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 5.1% of TELA Bio shares are held by insiders. Comparatively, 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

TELA Bio beats Check-Cap on 8 of the 15 factors compared between the two stocks.

How does Check-Cap compare to InspireMD?

InspireMD (NYSE:NSPR) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

InspireMD currently has a consensus price target of $4.50, suggesting a potential upside of 543.78%. Given InspireMD's stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Check-Cap had 1 more articles in the media than InspireMD. MarketBeat recorded 1 mentions for Check-Cap and 0 mentions for InspireMD. Check-Cap's average media sentiment score of 0.36 beat InspireMD's score of 0.00 indicating that Check-Cap is being referred to more favorably in the news media.

Company	Overall Sentiment
InspireMD	Neutral
Check-Cap	Neutral

Check-Cap has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. Check-Cap's return on equity of 0.00% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
Check-Cap	N/A	N/A	N/A

44.8% of InspireMD shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 29.7% of InspireMD shares are held by insiders. Comparatively, 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Check-Cap has lower revenue, but higher earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$10.85M	3.02	-$19.92M	-$0.73	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

InspireMD has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Check-Cap has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

Summary

InspireMD beats Check-Cap on 8 of the 15 factors compared between the two stocks.

How does Check-Cap compare to PetVivo?

Check-Cap (NASDAQ:MBAI) and PetVivo (NASDAQ:PETV) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Check-Cap has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Check-Cap's return on equity of 0.00% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
PetVivo	-902.82%	-4,813.07%	-281.78%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, PetVivo had 4 more articles in the media than Check-Cap. MarketBeat recorded 5 mentions for PetVivo and 1 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.36 beat PetVivo's score of 0.32 indicating that Check-Cap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Check-Cap	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PetVivo	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Check-Cap has higher earnings, but lower revenue than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
PetVivo	$1.05M	29.87	-$10.95M	-$0.38	N/A

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 0.5% of Check-Cap shares are held by company insiders. Comparatively, 10.8% of PetVivo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Check-Cap has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, PetVivo has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Summary

Check-Cap beats PetVivo on 7 of the 13 factors compared between the two stocks.

Get Check-Cap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBAI vs. The Competition

Export

Metric	Check-Cap	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$8.31M	$3.23B	$4.50B	$12.41B
Dividend Yield	N/A	N/A	17.12%	6.63%
P/E Ratio	-0.41	20.07	23.91	24.72
Price / Sales	N/A	356.14	154.91	111.10
Price / Cash	2.18	8.98	35.72	58.15
Price / Book	2.43	5.79	13.25	6.45
Net Income	$4.14M	$7.39M	$113.80M	$336.86M
7 Day Performance	4.59%	0.65%	0.92%	1.38%
1 Month Performance	-25.49%	-1.04%	-1.42%	1.70%
1 Year Performance	N/A	-40.05%	10.45%	24.00%

Check-Cap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBAI Check-Cap	0.3458 of 5 stars	$1.14 flat	N/A	N/A	$8.31M	N/A	N/A	80	Short Interest Increase
NTRB Nutriband	0.1271 of 5 stars	$3.11 +1.8%	N/A	-71.5%	$37.74M	$1.80M	N/A	10	Positive News Analyst Upgrade
NEPH Nephros	2.421 of 5 stars	$3.29 -0.4%	$6.00 +82.6%	-14.6%	$35.68M	$19.12M	46.95	30	Gap Up
TELA TELA Bio	2.8191 of 5 stars	$0.76 -3.4%	$2.20 +189.9%	-62.2%	$33.98M	$80.28M	N/A	120
NSPR InspireMD	3.5954 of 5 stars	$0.71 +1.6%	$4.50 +532.0%	-68.7%	$33.35M	$10.85M	N/A	50	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBAI) was last updated on 7/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Check-Cap (MBAI) Competitors